Related Experiment Video
Updated: Apr 30, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.1K
A modest proposal for dropping poor arms in clinical trials
Michael A Proschan1, Lori E Dodd
1National Institute of Allergy and Infectious Diseases, Bethesda, MD, U.S.A.
Statistics in Medicine
|April 24, 2014
Summary
This study introduces a streamlined clinical trial procedure for evaluating multiple treatments against a control. It uses negative results from some treatment arms to reduce evidence requirements for others, improving efficiency in multi-arm trials.
Area of Science:
- Clinical Trials Methodology
- Biostatistics
- Pharmaceutical Research
Background:
- Increasing complexity of phase III clinical trials with multiple treatment arms.
- Need for efficient evaluation of new therapies against active controls.
- Potential for some treatment arms to underperform compared to controls.
Purpose of the Study:
- To present a simplified procedure for clinical trials comparing multiple arms to a control.
- To leverage negative results from certain comparisons to decrease evidence thresholds for others.
- To enhance the efficiency of multi-arm clinical trial designs.
Main Methods:
- Development of a novel statistical procedure for multi-arm clinical trials.
- Analytical evaluation of the procedure's statistical properties.
- Application of the procedure to multi-arm multi-stage designs.
Main Results:
- The proposed procedure offers a method to adjust evidence requirements based on comparative performance.
- Negative results in some arms can reduce the statistical burden for other arms.
- The procedure is analytically supported and applicable to complex trial designs.
Conclusions:
- The introduced procedure simplifies clinical trial evaluations by utilizing comparative data.
- This approach enhances the efficiency of multi-arm trials, particularly phase III studies.
- The method provides a statistically sound way to manage trials with multiple treatment options.
Related Concept Videos
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
248
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
248
01:16Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
01:28Dosage Regimens: Designs and Approaches
600
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
600
01:13Bioequivalence studies: Biowaivers
430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430